- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04538872
Learning Strategies for Improving Dual Task Performance in Multiple Sclerosis (StraDiMS)
This study is a randomized controlled study in which we aim to include 60 persons with Multiple Sclerosis and 30 healthy controls. Two different learning strategies, an explicit and an implicit one, will be compared on effects on dual task performance. Further, clinical profile associated with these effects, and brain activity measured by functional near-infrared spectroscopy during dual tasking will be investigated.
To this end, the study will cover 4 days:
Day 1: examine clinical profile; Day 2: baseline dual task measures; Day 3: experimental learning paradigm with subjects randomly assigned to either the implicit or the explicit learning condition.
Day 4: delayed retention dual task and fNIRS measures.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Overpelt, Belgium, 3900
- Noorderhart
-
Steenokkerzeel, Belgium, 1820
- National MS Center Melsbroek
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- all participants: minimal cognitive function (MoCA ≥ 26)
Persons with MS:
- Diagnosis of MS
- EDSS 2.0 - 5.5
- No relapse within the past 30 days.
- Able to walk minimally 6 minutes consecutively and to step over the stepping platform without aid.
Exclusion Criteria:
- Other medical conditions interfering with mobility.
- Other neurological conditions.
- Not able to understand instructions.
- Major (unresolvable) problems with hearing or vision.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: OTHER
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: MS group implicit
|
participants perform a goal-directed stepping task and try to react as fast as possible by stepping on a tile that lights up.
Response time (the time between the tile lighting up and the participant stepping on the tile) is the outcome measure of the task.
The implicit learning conditions and the explicit learning condition differ from each other in the instructions given prior to the task.
The latter group will get more knowledge on the task than the former.
|
EXPERIMENTAL: MS group explicit
|
participants perform a goal-directed stepping task and try to react as fast as possible by stepping on a tile that lights up.
Response time (the time between the tile lighting up and the participant stepping on the tile) is the outcome measure of the task.
The implicit learning conditions and the explicit learning condition differ from each other in the instructions given prior to the task.
The latter group will get more knowledge on the task than the former.
|
ACTIVE_COMPARATOR: HC group implicit (Healthy Controls)
|
participants perform a goal-directed stepping task and try to react as fast as possible by stepping on a tile that lights up.
Response time (the time between the tile lighting up and the participant stepping on the tile) is the outcome measure of the task.
The implicit learning conditions and the explicit learning condition differ from each other in the instructions given prior to the task.
The latter group will get more knowledge on the task than the former.
|
ACTIVE_COMPARATOR: HC group explicit (Healthy controls)
|
participants perform a goal-directed stepping task and try to react as fast as possible by stepping on a tile that lights up.
Response time (the time between the tile lighting up and the participant stepping on the tile) is the outcome measure of the task.
The implicit learning conditions and the explicit learning condition differ from each other in the instructions given prior to the task.
The latter group will get more knowledge on the task than the former.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Dual task (STEP + substraction sevens)
Time Frame: day 2
|
participants will step as fast as possible on a tile that lights up in a goal-directed stepping task on a platform consisting of 21 stepping tiles.
Concurrently, they will perform a cognitive task in which they continuously subtract sevens, starting from a 3-digit given start number.
Duration of the task depends on the speed of the participant (42 steps).
|
day 2
|
Dual task (STEP + substraction sevens)
Time Frame: day 4
|
participants will step as fast as possible on a tile that lights up in a goal-directed stepping task on a platform consisting of 21 stepping tiles.
Concurrently, they will perform a cognitive task in which they continuously subtract sevens, starting from a 3-digit given start number.
Duration of the task depends on the speed of the participant (42 steps).
|
day 4
|
Dual task (STEP + phonetic word list generation)
Time Frame: day 2
|
participants will step as fast as possible on a tile that lights up in a goal-directed stepping task on a platform consisting of 21 stepping tiles.
Concurrently, they will perform a cognitive task in which they try to come up with as many words as possible starting with a given letter.
Duration of the task depends on the speed of the participant (42 steps).
|
day 2
|
Dual task (STEP + phonetic word list generation)
Time Frame: day 4
|
participants will step as fast as possible on a tile that lights up in a goal-directed stepping task on a platform consisting of 21 stepping tiles.
Concurrently, they will perform a cognitive task in which they try to come up with as many words as possible starting with a given letter.
Duration of the task depends on the speed of the participant (42 steps).
|
day 4
|
Dual task (STEP + Auditory vigilance)
Time Frame: day 2
|
participants will step as fast as possible on a tile that lights up in a goal-directed stepping task on a platform consisting of 21 stepping tiles.
Concurrently, they will perform a cognitive task in which they hear a string of letters (1 every 2.5 seconds) and are asked to respond as quickly as possible when they hear the target letter 'L' or 'R'.
Duration of the task depends on the speed of the participant (42 steps).
|
day 2
|
Dual task (STEP + Auditory vigilance)
Time Frame: day 4
|
participants will step as fast as possible on a tile that lights up in a goal-directed stepping task on a platform consisting of 21 stepping tiles.
Concurrently, they will perform a cognitive task in which they hear a string of letters (1 every 2.5 seconds) and are asked to respond as quickly as possible when they hear the target letter 'L' or 'R'.
Duration of the task depends on the speed of the participant (42 steps).
|
day 4
|
Dual Task (WALK + Subtraction sevens)
Time Frame: day 2
|
participants will walk on their comfortable, preferred walking speed on a 30-meter walkway.
Concurrently, they will perform a cognitive task in which they continuously subtract sevens, starting from a 3-digit given start number.
Duration of the task is 30 seconds.
|
day 2
|
Dual Task (WALK + Subtraction sevens)
Time Frame: day 4
|
participants will walk on their comfortable, preferred walking speed on a 30-meter walkway.
Concurrently, they will perform a cognitive task in which they continuously subtract sevens, starting from a 3-digit given start number.
Duration of the task is 30 seconds.
|
day 4
|
Dual Task (WALK + Word list generation (phonetic)
Time Frame: day 2
|
participants will walk on their comfortable, preferred walking speed on a 30-meter walkway.
Concurrently, they will perform a cognitive task in which they try to come up with as many words as possible starting with a given letter.
Duration of the task is 30 seconds.
|
day 2
|
Dual Task (WALK + Word list generation (phonetic)
Time Frame: day 4
|
participants will walk on their comfortable, preferred walking speed on a 30-meter walkway.
Concurrently, they will perform a cognitive task in which they try to come up with as many words as possible starting with a given letter.
Duration of the task is 30 seconds.
|
day 4
|
Dual Task (WALK + Auditory vigilance)
Time Frame: day 2
|
participants will walk on their comfortable, preferred walking speed on a 30-meter walkway.
Concurrently, they will perform a cognitive task in which they hear a string of letters (1 every 2.5 seconds) and are asked to respond as quickly as possible when they hear the target letter 'L' or 'R'.
Duration of the task is 30 seconds.
|
day 2
|
Dual Task (WALK + Auditory vigilance)
Time Frame: day 4
|
participants will walk on their comfortable, preferred walking speed on a 30-meter walkway.
Concurrently, they will perform a cognitive task in which they hear a string of letters (1 every 2.5 seconds) and are asked to respond as quickly as possible when they hear the target letter 'L' or 'R'.
Duration of the task is 30 seconds.
|
day 4
|
learning measure
Time Frame: Day 3
|
participants will step as fast as possible on a tile that lights up in a goal-directed stepping task on a platform consisting of 21 stepping tiles.
The outcome measure on this task is response time (time from the moment the tile lights up, until the participant steps on the tile).
|
Day 3
|
fNIRS measure (functional near-infrared spectroscopy)
Time Frame: day 4
|
a block-design test with 3 tasks (cognitive ST, motor ST and DT) of 25 seconds per task-block (repeated 5 times) will be conducted with a functional near-infrared spectroscopy (fNIRS) neuroimaging system to measure hemoglobin changes during performance of the task and compared between single task and dual task conditions and between groups.
Besides, fNIRS will be used during 1 task related to the learning-paradigm.
|
day 4
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
weight
Time Frame: day 1
|
day 1
|
|
Age
Time Frame: day 1
|
day 1
|
|
height
Time Frame: day 1
|
day 1
|
|
educational level questionnaire
Time Frame: day 1
|
day 1
|
|
date of diagnosis questionnaire
Time Frame: day 1
|
day 1
|
|
type of MS questionnaire
Time Frame: day 1
|
day 1
|
|
EDSS
Time Frame: day 1
|
Expanded Disability Status Scale (EDSS)
|
day 1
|
Digit span forwards visually
Time Frame: day 1
|
day 1
|
|
Brief Visuospatial Memory Test (BVMT)
Time Frame: day 1
|
day 1
|
|
10/36 Spatial Recall test (SPART)
Time Frame: day 1
|
day 1
|
|
Symbol Digit Modalities Test (SDMT)
Time Frame: day 1
|
day 1
|
|
Paced Auditory Serial Addition Test (PASAT)-3 seconds
Time Frame: day 1
|
day 1
|
|
Digit Span backwards auditory
Time Frame: day 1
|
day 1
|
|
6 minute walking test (6MWT)
Time Frame: day 1
|
day 1
|
|
Timed-Up and Go (TUG)
Time Frame: day 1
|
day 1
|
|
Timed 25 Foot Walk (T25FW)
Time Frame: day 1
|
day 1
|
|
4 square stepping test (FSST)
Time Frame: day 1
|
day 1
|
|
Berg Balance Scale (BBS)
Time Frame: day 1
|
day 1
|
|
Tandem Walk 3m
Time Frame: day 1
|
day 1
|
|
Motricity Index
Time Frame: day 1
|
day 1
|
|
Movement specific reinvestment scale (MSRS)
Time Frame: day 1
|
day 1
|
|
MS Neuropsychological screening questionnaire (MSNQ)
Time Frame: day 1
|
day 1
|
|
Multiple Sclerosis Walking Scale (MSWS-12)
Time Frame: day 1
|
day 1
|
|
Modified fatigue impact scale (MFIS)
Time Frame: day 1
|
day 1
|
|
Activities-specific Balance Confidence scale (ABC)
Time Frame: day 1
|
day 1
|
|
Dual Task Questionnaire (DTQ)
Time Frame: day 1
|
day 1
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- StraDiMS-001
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsRecruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
University of California, San FranciscoUnited States Department of DefenseRecruitingMultiple Sclerosis, Chronic Progressive | Multiple Sclerosis, Relapsing-Remitting | Multiple Sclerosis (MS) | Multiple Sclerosis Relapse | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis Brain Lesion | Multiple Sclerosis BenignUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Brigham and Women's HospitalMassachusetts General HospitalRecruitingMultiple Sclerosis | Relapsing Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on StraDiMS implicit
-
University of Colorado, DenverNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)CompletedObesity | Overweight | Feeding BehaviorUnited States
-
University of Colorado, DenverNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)RecruitingOverweight and ObesityUnited States
-
Brigham and Women's HospitalMassachusetts General Hospital; National Institute on Aging (NIA); Virginia Commonwealth...Active, not recruitingOsteoarthritis | Rheumatoid Arthritis | Systemic Lupus Erythematosus | Inflammatory ArthritisUnited States
-
Centre Hospitalier Universitaire, AmiensCentre Hospitalier Pinel d'AmiensRecruitingSuicide | Implicit Association Test | Prevention, Suicide | Suicide Risk FactorFrance
-
The Royal Bournemouth HospitalUniversity of SouthamptonUnknown
-
University of MinnesotaRecruitingDevelopmental Language Disorder | Explicit Intervention | Grammatical LanguageUnited States
-
Duke-NUS Graduate Medical SchoolWorld Bank; Public Health Authority of Saudi ArabiaCompleted
-
Abant Izzet Baysal UniversityRecruitingCerebral Palsy, SpasticTurkey
-
University of Southern CaliforniaRecruiting
-
Teesside UniversityCompleted